Anticalins small engineered binding proteins based on the lipocalin scaffold.
Anticalins are a novel class of small, robust proteins with designed ligand-binding properties derived from the natural lipocalin scaffold. Due to their compact molecular architecture, comprising a single polypeptide chain, they provide several benefits as protein therapeutics, such as high target specificity, good tissue penetration, low immunogenicity, tunable plasma half-life, efficient Escherichia coli expression, and suitability for furnishing with additional effector functions via genetic fusion or chemical conjugation. The lipocalins are a widespread family of proteins that naturally serve in many organisms, including humans, for the transport, storage, or sequestration of small biological compounds like vitamins and hormones. Their fold is dominated by an eight-stranded antiparallel β-barrel, which is open to the solvent at one end. There, four loops connect the β-strands in a pairwise manner and, altogether, they form the entry to a ligand-binding site. This loop region can be engineered via site-directed random mutagenesis in combination with genetic library selection techniques to yield "Anticalins" with exquisite specificities-and down to picomolar affinities-for prescribed molecular targets of either hapten or antigen type. Several Anticalins directed against medically relevant disease targets have been successfully engineered and can be applied, for example, for the blocking of soluble signaling factors or cell surface receptors or for tissue-specific drug targeting. While natural lipocalins were already subject to clinical studies in the past, a first Anticalin has completed Phase I trials in 2011, thus paving the way for the broad application of Anticalins as a promising novel class of biopharmaceuticals.
Lehrstuhl für Biologische Chemie, Technische Universität München, Freising-Weihenstephan, Germany.
Michaela
M
Gebauer
Arne
A
Skerra
D000209:Acute-Phase Proteins / Q000138:chemical synthesis / Q000737:chemistry* / Q000627:therapeutic use; D000818:Animals; D002352:Carrier Proteins / Q000138:chemical synthesis / Q000737:chemistry* / Q000627:therapeutic use; D003001:Cloning, Molecular; D016503:Drug Delivery Systems / Q000379:methods*; D004797:Enzyme-Linked Immunosorbent Assay; D004926:Escherichia coli / Q000737:chemistry; D005822:Genetic Vectors / Q000737:chemistry; D006801:Humans; D000071068:Lipocalin-2; D054834:Lipocalins / Q000138:chemical synthesis / Q000737:chemistry* / Q000627:therapeutic use; D016297:Mutagenesis, Site-Directed / Q000379:methods; D019151:Peptide Library; D010957:Plasmids / Q000737:chemistry; D015202:Protein Engineering / Q000379:methods; D011518:Proto-Oncogene Proteins / Q000138:chemical synthesis / Q000737:chemistry* / Q000627:therapeutic use; D011994:Recombinant Proteins / Q000138:chemical synthesis / Q000737:chemistry / Q000627:therapeutic use; D013379:Substrate Specificity
D000209:Acute-Phase Proteins; D002352:Carrier Proteins; C489506:LCN2 protein, human; D000071068:Lipocalin-2; D054834:Lipocalins; D019151:Peptide Library; D011518:Proto-Oncogene Proteins; D011994:Recombinant Proteins